Sensei Biotherapeutics (NASDAQ:SNSE) Releases Earnings Results, Beats Expectations By $0.01 EPS

Sensei Biotherapeutics (NASDAQ:SNSE) issued its quarterly earnings results on Tuesday. The company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.01, Yahoo Finance reports.

Sensei Biotherapeutics Stock Performance

SNSE traded down $0.04 during trading hours on Wednesday, hitting $0.61. The stock had a trading volume of 11,478 shares, compared to its average volume of 132,853. The stock has a market cap of $15.35 million, a PE ratio of -0.54 and a beta of 0.03. Sensei Biotherapeutics has a 1 year low of $0.51 and a 1 year high of $1.94. The company has a quick ratio of 12.07, a current ratio of 12.07 and a debt-to-equity ratio of 0.01. The company’s fifty day simple moving average is $0.67 and its 200 day simple moving average is $0.91.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on SNSE shares. Citigroup reiterated a “buy” rating and set a $4.00 target price on shares of Sensei Biotherapeutics in a research note on Monday, June 3rd. Stephens reaffirmed an “overweight” rating and issued a $5.00 price objective on shares of Sensei Biotherapeutics in a research report on Friday, May 24th. Finally, HC Wainwright reissued a “buy” rating and set a $4.00 target price on shares of Sensei Biotherapeutics in a research report on Wednesday.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.